Salvage Settings, Duration, and Next Steps in Very High-Risk Prostate Cancer

Dr. Tamim Niazi discusses clinical strategies for high-risk prostate cancer, comparing different treatment cohorts and the efficacy of darolutamide. He emphasizes the importance of early staging and personalized treatment plans based on risk assessment tools.
Why it matters
Advancements in salvage therapy and risk stratification are essential for improving long-term survival rates and quality of life for prostate cancer patients.
Tamim Niazi, MDCM, begins by separating DASL-HiCaP's (NCT04136353) post-prostatectomy cohort from EMBARK (NCT02319837). EMBARK enrolled patients who were not eligible for salvage curative treatment or had already received it, he explains, whereas DASL-HiCaP enrolled patients still eligible for cure, who received 24 months of androgen deprivation therapy (ADT) and locoregional radiation therapy with or without darolutamide (Nubeqa). Although event numbers in the salvage setting are small, he reports an HR of about 0.1 in favor of darolutamide and expects it to remain below 0.5 as data mature.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in